Literature DB >> 28081969

Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA - Results of an international collaborative study.

Sylvie Morgeaux1, Bertrand Poirier2, C Ian Ragan3, Dianna Wilkinson4, Ulrich Arabin5, Françoise Guinet-Morlot6, Robin Levis7, Heidi Meyer8, Patrice Riou6, Shahjahan Shaid5, Dmitriy Volokhov7, Noël Tordo9, Jean-Michel Chapsal10.   

Abstract

Three different ELISAs quantifying rabies glycoprotein were evaluated as in vitro alternatives to the National Institutes of Health (NIH) in vivo potency test for batch release of human rabies vaccines. The evaluation was carried out as an international collaborative study supported by the European Partnership for Alternatives to Animal Testing (EPAA). This pre-validation study, the results of which are presented in this paper, compared three different ELISA designs, assessing their within- and between-laboratory precision. One of the ELISA designs was proposed to the European Directorate for the Quality of Medicines & HealthCare (EDQM) and accepted for an international collaborative study under the umbrella of the Biological Standardisation Programme.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ELISA; Human; In vitro; NIH test; Rabies; Vaccine

Mesh:

Substances:

Year:  2017        PMID: 28081969     DOI: 10.1016/j.vaccine.2016.12.039

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  A novel ELISA for quantification of glycoprotein in human rabies vaccines using a clinically proven virus neutralizing human monoclonal antibody.

Authors:  Sunil Gairola; Manish Gautam; Satish Waghmare
Journal:  Hum Vaccin Immunother       Date:  2020-01-23       Impact factor: 3.452

2.  Serological profiling of rabies antibodies by enzyme-linked immunosorbent assay and its comparative analysis with rapid fluorescent focus inhibition test in mouse model.

Authors:  Ashis Debnath; Dinesh C Pathak; Narayan Ramamurthy; Gulam Mohd; A B Pandey; Vikramaditya Upmanyu; A K Tiwari; R Saravanan; Madhan Mohan Chellappa; Sohini Dey
Journal:  Vet World       Date:  2019-01-23

3.  Rabies Vaccine Characterization by Nanoparticle Tracking Analysis.

Authors:  Navarro Sanchez; D Soulet; E Bonnet; F Guinchard; S Marco; E Vetter; N Nougarede
Journal:  Sci Rep       Date:  2020-05-18       Impact factor: 4.379

4.  Animal testing for vaccines. Implementing replacement, reduction and refinement: challenges and priorities.

Authors:  Arnoud Akkermans; Jean-Michel Chapsal; Eliana M Coccia; Hilde Depraetere; Jean-François Dierick; Parichat Duangkhae; Sunil Goel; Marlies Halder; Coenraad Hendriksen; Robin Levis; Koraphong Pinyosukhee; Dieter Pullirsch; Gautam Sanyal; Li Shi; Robert Sitrin; Dean Smith; Paul Stickings; Eriko Terao; Sylvie Uhlrich; Laura Viviani; Jim Webster
Journal:  Biologicals       Date:  2020-10-08       Impact factor: 1.856

5.  Alternative Methods to Current In Vivo Procedures to Address the 3Rs Tenet in Rabies Proficiency Testing.

Authors:  Maira Zorzan; Morgane Gourlaouen; Stefania Leopardi; Paola De Benedictis
Journal:  Viruses       Date:  2022-07-31       Impact factor: 5.818

Review 6.  Prophylactic Hepatitis E Vaccines: Antigenic Analysis and Serological Evaluation.

Authors:  Yike Li; Xiaofen Huang; Zhigang Zhang; Shaowei Li; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Viruses       Date:  2020-01-16       Impact factor: 5.048

7.  Development of a double-recombinant antibody sandwich ELISA for quantitative detection of epsilon toxoid concentration in inactivated Clostridium perfringens vaccines.

Authors:  Maryam Alibeiki; Mehdi Golchin; Mohammad Tabatabaei
Journal:  BMC Vet Res       Date:  2020-09-29       Impact factor: 2.741

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.